Analgesic effect of intravenous lidocaïne and its mechanisms in patients suffering from chronic inflammatory bowel disease (IBD) with abdominal pain.

You likely can't join if

• The exclusion criteria for WP1 and WP2 will be the following: renal insufficiency (exclueded by a blood sample from maximum one year), hepatic insufficiency (exclueded by a blood sample from maximum one year), hypersensitivity to the active ingredient or to one of the excipients or to local anesthetics of the amide type, cardiac conduction disorders, cardiac insufficiency, ongoing anticoagulant therapy, history of convulsion, injection site infection, shock state, history of malignant hyperthermia, refusal of the patient, pregnancy, breast-feeding woman, ongoing treatment with analgesics specifically targeting neuropathic pain (pregabalin, gabapentin, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRI), serotonin and noradrenaline reuptake inhibitors (SNRI)), neurological or psychiatric disorders, seizures, history of alcohol or drug abuse. In addition, treatment of IBD cannot be modified during the trial. Patients are also excluded if they take medications that have interactions with lidocaine, including beta-blockers, digitalin derivatives, cimetidine, barbituric, rifampicin, isoprenaline, glucagon, phenytoin, tocainide, mexiletine, and amiodarone. An acute/sudden, severe, sharp and constant or worsening in intensity abdominal pain is also an exclusion criterion. For WP2, contraindications to MRI will be added as exclusion criteria, including metallic devices such as a pacemaker, vascular clips, some ocular implants, cochlear implants, stent for less than 6 months, …). A complete metal checklist will be verified with each participant before allowing them to enter the MRI suite.